Opportunity
Systems for Phenotypic Evaluation, Clinical Trajectories, Response, and Agency (SPECTRA)
Response due
October 21, 2026
- Agency
- Advanced Research Projects Agency for Health (arpa-H)
- Estimated value
- Not stated
Amendment 1 (10/14/2026): Update due dates and/or times of all TAs SPECTRA will identify and act on autism trajectories, the evolving developmental paths individuals follow across the lifespan from the prenatal period through aging, spanning autism characteristics, co-occurring conditions, and functional outcomes together with the genetic, biological, behavioral, iatrogenic (medical influences), environmental factors and their nonlinear interactions. Rather than examining these factors in isolation, SPECTRA will examine how they combine and interact, including their nonlinear interactions, to produce autism and its co-occurring conditions over time. SPECTRA will also develop technologies that serve two purposes at once: extending reliable assessment beyond the clinic while improving everyday communication, function, and quality of life. The same tools people use to live more fully will also generate the data that drive measurement and personalized care.
Key dates
- Posted
- October 14, 2026
- Response due
- October 21, 2026
Who is this buyer
Organization
Buying history
- Records6 total
- Opportunities / awards3 / 0
- ActiveJuly 28, 2026 – October 14, 2026
What they buy
- Clinical (4)
- Administrative (2)
Set-asides used
- Small Business Set Aside - Total (1)
Also open from this buyer
- Systems for Phenotypic Evaluation, Clinical Trajectories, Response, and Agency (SPECTRA)Due October 18, 2026 · Clinical
- Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) Innovative Solutions OpeningDue November 10, 2026 · Clinical
View source document →
Source link on sam.gov.
Source record
- Buyer type
- Federal
- Jurisdiction
- Federal (US)
- Category
- Clinical
- Set-aside
- Not stated
- NAICS
- 541715
- PSC
- AN13